This page shows the latest Kisqali news and features for those working in and with pharma, biotech and healthcare.
Novartis’ Kisqali (ribociclib) is far behind Pfizer’s drug (but expected to hit $1.6bn in 2022 according to EvaluatePharma), with Verzenios expected to give Kisquali competition for second place in ... However, analysts says Verzenios has an
Among these, Novartis’ CDK4/6 inhibitor Kisqali (ribociclib) was recommended for the treatment of women with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer in combination with fulvestrant
6 inhibitor, a newer drug group which includes Novartis’ own Kisqali (ribociclib), Pfizer’s Ibrance (palbociclib) and Eli Lilly’s Verzenio (abemaciclib).
Sales in the second quarter reached almost $58m, a $20m increase on the first quarter, and Lilly claims it is outperforming Kisqali when it comes to new prescriptions. ... Kisqali’s second-quarter haul was $59m, up from $44m in the first quarter, with
own Kisqali (ribociclib) and Eli Lilly’s Verzenio (abemaciclib).
status. However, just weeks after Novartis released promising progressive-free survival data for its Kisqali combo, Pfizer saw its drug flop on the harder overall survival (OS) endpoint.
More from news
Approximately 6 fully matching, plus 17 partially matching documents found.
Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...